Singapore-based biotechnology firm Tessa Therapeutics (Tessa) has come a long way from the Singapore cafe where the idea of its inception was hatched.
Born over a discussion eight years ago between an immunologist and an oncologist, it is today ahead in the race to turn cancer patients' own immune cells (T-cells) against the tumours in their bodies.
TO READ THE FULL ARTICLE
Thank you for reading The Straits Times
You have reached one of our Premium stories. To continue reading, get access now or log in if you are a subscriber.
What is Premium?